These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21649451)
1. Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer. Lyseng-Williamson KA CNS Drugs; 2011 Jun; 25(6):511-22. PubMed ID: 21649451 [TBL] [Abstract][Full Text] [Related]
2. Fentanyl pectin nasal spray: a novel intranasal delivery method for the treatment of breakthrough cancer pain. Bulloch MN; Hutchison AM Expert Rev Clin Pharmacol; 2013 Jan; 6(1):9-22. PubMed ID: 23272789 [TBL] [Abstract][Full Text] [Related]
3. Fentanyl nasal spray for the treatment of cancer pain. Mystakidou K; Panagiotou I; Gouliamos A Expert Opin Pharmacother; 2011 Jul; 12(10):1653-9. PubMed ID: 21609189 [TBL] [Abstract][Full Text] [Related]
4. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Portenoy RK; Burton AW; Gabrail N; Taylor D; Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358 [TBL] [Abstract][Full Text] [Related]
5. Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer. Torres LM; Revnic J; Knight AD; Perelman M J Palliat Med; 2014 Oct; 17(10):1150-7. PubMed ID: 25211772 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R; J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892 [TBL] [Abstract][Full Text] [Related]
7. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain. Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821 [TBL] [Abstract][Full Text] [Related]
8. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen. Mercadante S; Prestia G; Adile C; Casuccio A J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001 [TBL] [Abstract][Full Text] [Related]
9. Fentanyl pectin nasal spray for breakthrough cancer pain. Taylor DR; Gabrail N Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576 [TBL] [Abstract][Full Text] [Related]
10. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794 [TBL] [Abstract][Full Text] [Related]
11. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386 [TBL] [Abstract][Full Text] [Related]
15. Evidence-based treatment of cancer-related breakthrough pain with opioids. Zeppetella G J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185 [TBL] [Abstract][Full Text] [Related]
16. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Simpson DM; Messina J; Xie F; Hale M Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282 [TBL] [Abstract][Full Text] [Related]
17. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients. Elsner F; Zeppetella G; Porta-Sales J; Tagarro I Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159 [TBL] [Abstract][Full Text] [Related]
18. Fentanyl nasal spray (Lazanda) for pain. Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454 [TBL] [Abstract][Full Text] [Related]
19. Fentanyl pectin nasal spray for breakthrough cancer pain. Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759 [No Abstract] [Full Text] [Related]
20. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study. Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]